Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Effectiveness of Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines (EMPACT Study).

NCT05271162 is registered in ClinicalTrials.gov with Maria Sklodowska-Curie National Research Institute of Oncology as lead sponsor.

NCT NCT05271162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05271162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Effectiveness of Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines (EMPACT Study).
Lead sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 30, 2023
Completion date
February 24, 2028
Enrollment
220 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cardiotoxicity